HR+, HER2- Early Breast Cancer

Save for later Saved

Understanding Recurrence: High-Risk Features for Patients With Early Breast Cancer

Early breast cancer (EBC) recurrence: some clinical features of high-risk disease

Patients with hormone receptor–positive (HR+), HER2-negative (HER2-) EBC at high risk of recurrence may present with 1-3 positive ALNs with grade 3 disease or tumor size ≥5 cm, or ≥4 positive ALNs,.1

Factors associated with a high risk of early breast cancer recurrence include 1 to 3 positive ALNs with grade 3 disease or tumor size greater than or equal to 5 cm or greater than or equal to 4 positive ALNs.

Factors associated with a high risk of early breast cancer recurrence include 1 to 3 positive ALNs with grade 3 disease or tumor size greater than or equal to 5 cm or greater than or equal to 4 positive ALNs.

Putting it into practice: EBC patient case studies

Patient case 1
high-risk-patient-id-page-patientcase1
Patient case 2
high-risk-patient-id-page-patientcase2

Downloadable PDFs

INFOGRAPHIC: EBC Patients at a High Risk of Recurrence Case Studies (PDF)

https://main--lusa-lillymeded-aem-us--elilillyco.aem.page/medical/fragments/figure-captions/high-risk-patient-id-page-video1

Defining high-risk HR+, HER2- early breast cancer

Dr. O’Shaughnessy describes risk factors for HR+, HER2- breast cancer disease recurrence with in the first five years such as larger cancers, high nodal burden, grade 3 disease, Ki-67 score, and certain gene signatures.

https://main--lusa-lillymeded-aem-us--elilillyco.aem.page/medical/fragments/figure-captions/high-risk-patient-id-page-video2

Conveying risk for recurrence & importance of optimizing therapy to decrease that risk in HR+, HER2- EBC

Dr. O’Shaughnessy shares how she educates her patients on their risk of recurrence with HR+, HER2- early breast cancer (EBC).

References

  1. Sheffield KM, et al. Future Oncol. 2022;18(21):2667-2682.

VV-MED-154879